Stifel Maintains Buy on Nurix Therapeutics, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey maintains a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) with a $27 price target.
May 15, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Stephen Willey maintains a Buy rating on Nurix Therapeutics with a $27 price target, indicating confidence in the company's future performance.
The maintained Buy rating and $27 price target from Stifel suggests strong confidence in Nurix Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100